Marc Beer, Founder and Chairman
Marc is the former Chief Executive Officer of Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR). Aegerion is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. Marc took the company public in October 2010. The Company’s first marketed product, JUXTAPID® (lomitapide) was approved by the US Food and Drug Administration in December 2012 for homozygous familial hypercholesterolemia. During his tenure, JUXTAPID obtained marketing approval in 36 countries. Additionally, Aegerion acquired its second product, MYALEPT® (metreleptin), approved in the US for generalized lipodystrophy, an ultra-rare disease.
In April 2000, Marc became the Founding CEO of ViaCell (NASDAQ: VIAC), a biotechnology company specializing in the collection, preservation, and development of umbilical cord blood stem cells, and over a period of seven years led the company from its inception to a rapidly growing and robust commercial organization. Under Marc’s leadership, the company grew to more than 300 employees, went public in 2005 and was ultimately acquired in 2007 by PerkinElmer (NYSE: PKI).
While serving as CEO of ViaCell, Marc also served as a member of the board of directors of Erytech Pharma (NASDAQ: ERYP), a publicly traded biopharmaceutical company. Prior to ViaCell, Marc held various positions within Genzyme, most recently as Vice President of Global Marketing where he was responsible for the commercial launch of several products addressing rare disease populations on a global scale.
Prior to Genzyme, he held a variety of sales and marketing roles in the pharmaceutical and diagnostic divisions of Abbott Laboratories (NYSE: ABT). He also was a former member of the Mass Life Science Board of the Commonwealth of Massachusetts and served on the Biotechnology Industry Organization (BIO) Emerging Companies Section Governing Board.
Marc was also Founding Chairman of the board of directors and chairman of the compensation committee of Good Start Genetics, Inc., recently acquired by InVitae (NASDAQ: NVTA). He is the Founding Chairman of the board, chairman of the compensation committee and member of the audit committee of Minerva Neurosciences Inc. (NASDAQ: NERV); and a member of the Miami University Business Advisory Council and previously a member of the Notre Dame Research and Commercialization Advisory Committee and Notre Dame Graduate Studies Research and Advisory Council. Marc holds a BS from Miami University (Ohio).